Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: Comparison with vascular endothelial growth factor, tumor necrosis factor and interleukin-1β-mediated breakdown

Journal of Neuroscience Research

Volumn 49, Issue 3, 1997, Pages 268-280

  Luna, Jose D ^a,c   Chan, Chi Chao ^b   Derevjanik, Nancy L ^a   Mahlow, Jeremy ^a   Chiu, Charlie ^a   Peng, Bo ^b   Tobe, Takao ^a   Campochiaro, Peter A ^a   Vinores, Stanley A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c Fundacion VER   (Argentina)

Author keywords

Autoimmune disease; Cyclosporine; Dexamethasone; Growth factors; Inflammatory mediators; Thromboxane synthetase; Vesicular transport

Indexed keywords

ALBUMINOID; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BLOOD RETINA BARRIER; CONTROLLED STUDY; DIAGNOSIS; FEMALE; HISTOPATHOLOGY; INTRACELLULAR TRANSPORT; INTRAVITREAL DRUG ADMINISTRATION; MEMBRANE VESICLE; NONHUMAN; PIGMENT DISORDER; PRIORITY JOURNAL; RABBIT; RAT; TIGHT JUNCTION; UVEORETINITIS;

ALBUMINS; ANIMALS; AUTOIMMUNE DISEASES; BLOOD-RETINAL BARRIER; ENDOTHELIAL GROWTH FACTORS; FEMALE; INJECTIONS; INTERLEUKIN-1; LYMPHOKINES; MICROSCOPY, ELECTRON; RABBITS; RATS; RATS, INBRED LEW; RETINA; RETINITIS; TUMOR NECROSIS FACTOR-ALPHA; UVEA; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITREOUS BODY;

EID: 0030817998     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19970801)49:3<268::AID-JNR2>3.0.CO;2-A     Document Type: Article

References (83)

1. Ballestas ME, Benveniste EN (1995): Interleukin 1-β- and tumor necrosis factor-α-mediated regulation of ICAM-I gene expression in astrocytes requires protein kinase C activity. GLIA 14:267-278.
2. Bamforth SD, Greenwood J, Lightman SL (1994): The effect of interleukin-1β on blood-retinal barrier permeability of the anaesthetized rat. J Physiol 480:19P-20P.
3. Bamforth SD. Lightman S. Greenwood J (1996): The effect of TNFa and IL-6 on the permeability of the rat blood-retinal barrier in vivo. Acta Neuropathol 91:624-632.
4. Bazan NG, deAbreu MT, Bazan HE, Belfort R Jr (1990): Arachidonic acid cascade and platelet-activating factor in the network of eye inflammatory mediators: Therapeutic implications in uveitis. Int Ophthalmol 14:335-344.
5. Beutler B, Cerami A (1989): The biology of cachectin/TNF - A primary mediator of the host response. Annu Rev Immunol 7:625-655.
6. Brosnan CF, Claudio L. Tansey FA, Martiney J (1990): Mechanisms of autoimmune neuropathies. Ann Neurol 27:S75-S79.
7. Burger D, Dayer JM (1995): Inhibitory cytokines and cytokine inhibitors. Neurology 45:S39-S43.
8. Camussi G, Albano E, Tetta C, Bussolino F (1991): The molecular action of tumor necrosis factor-α. Eur J Biochem 202:3-14.
9. Cavallo MG, Pozzilli P, Thorpe R (1994): Cytokines and autoimmunity. Clin Exp Immunol 96:1-7.
10. Chan CC, Mochizuki M, Nussenblatt RB. Palestine AG, McAllister C, Gery I. BenEzra D (1985): T-lymphocyte subsets in experimental autoimmune uveitis. Clin Immunol Immunopathol 35:103-110.
11. Claudio L, Martiney JA, Brosnan CF (1994): Ultrastructural studies of the blood-retinal barrier after exposure to interleukin-1β or tumor necrosis factor-a. Lab Invest 70:850-861.
12. Dayer J-M, Burger D (1994): Interleukin-1. tumor necrosis factor and their specific inhibitors. Eur Cytokine Netw 5:563-571.
13. deKozak Y, Sakai J, Thillaye B, Faure JP (1981): S antigen-induced experimental autoimmune uveoretinitis in rats. Curr Eye Res 1:327-337.
14. deKozak Y, Naud M-C, Bellot J, Faure J-P. Hicks D (1994): Differential tumor necrosis factor expression by resident retinal cells from experimental uveitis-susceptible and -resistant rat strains. J Neuroimmunol 55:1-9.
15. Deli MA. Descamps L, Dehouck MP, Cecchelli R, Joo F, Abraham C, Torpier G (1995): Exposure of tumor necrosis factor-a to luminal membrane of bovine brain capillary endothelial cells cocultured with astrocytes induces a delayed increase of permeability and cytoplasmic stress fiber formation of actin. J Neurosci Res 41:717-726.
16. Derevjanik NL, Vinores SA, Peng B, Mahlow J, Chiu C, Campochiaro PA, Chan CC (1995): Effects of cyclosporine A (CsA), dexamethasone, and thromboxane synthetase inhibitor (COS-13080) on blood-retinal barrier breakdown in experimental autoimmune uveoretinitis: An ultrastructural study. Invest Ophthalmol Vis Sci 36:S534.
17. de Vos AF. Klaren VN, Kijlstra A (1994a): Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxininduced uveitis in the rat. Invest Ophthalmol Vis Sci 35:3873-3883.
18. deVos AF, van Haren MAC, Verhagen C, Hoekzema R, Kijlstra A (1994b): Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 35:1100-1106.
19. deVos AF, van Haren MA, Verhagen C, Hoekzema R, Kijlstra A (1995): Tumor necrosis factor-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Exp Eye Res 60:199-207.
20. deVries HE, Blom-Roosemalen, MCM. van Oosten M, deBoer AG, van Berkel TJC, Breimer DD, Kuiper J (1996): The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 64:37-43.
21. Dvorak HF, Brown LF, Detmar M. Dvorak AM (1995): Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 146: 1029-1039.
22. Eagle RC Jr (1984): Mechanisms of maculopathy. Ophthalmology 91:613-625.
23. Ferrara N, Henzel WJ (1989): Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-858.
24. β. Invest Ophthalmol Vis Sci 33:2120-2127.
25. β plus tumor necrosis factor-α. Graefes Arch Clin Exp Ophthalmol 233:94-100.
26. Forrester JV, Liversidge J, Towler H, McMenamin PG (1990): Comparison of clinical and experimental uveitis. Curr Eye Res 9(Suppl.):75-84.
27. Forrester JV, Liversidge J, Dua HS, Dick A, Harper F, McMenamin PG (1992): Experimental autoimmune uveoretinitis: A model system for immunomodulation. Curr Eye Res 11(Suppl.):33-40.
28. Franks WA, Limb GA, Stanford MR, Ogilvie J, Wolstencroft RA, Chignell AH, Dumonde DC (1992): Cytokines in human intraocular inflammation. Curr Eye Res 11:187-191.
29. Fukumura D, Salehi HA, Witwer B, Tuma RF, Melder RJ, Jain RK (1995): Tumor necrosis factor α-induced leukocyte adhesion in normal and tumor vessels-Effect of tumor type, transplantation site, and host strain. Cancer Res 55:4824-4829.
30. Goldberg MF (1979): Diseases affecting the blood-retinal barrier. In Cunha Vaz JG (ed): 'The Blood-Retinal Barriers.' New York: Plenum Press, pp 309-363.
31. Greenwood J (1992): The blood-retinal barrier in experimental autoimmune uveoretinitis (EAU): a review. Curr Eye Res 11:25-32.
32. Greenwood J, Howes R, Lightman S (1994): The blood-retinal barrier in experimental autoimmune uveoretinitis-Leukocyte interactions and functional damage. Lab Invest 70:39-52.
33. Greenwood J, Bamforth S, Wang Y, Devine L (1995): The blood-retinal barrier in immune-mediated diseases of the retina. In Greenwood J. Begley DJ, Segal MB (eds): 'New Concepts of a Blood-Brain Barrier.' New York: Plenum Press, pp 315-326.
34. 2 and E, in osteoblasts. J Clin Invest 93:2490-2496.
35. Hock JB (1992): Intracellular signal transduction and the control of endothelial permeability. Lab Invest 67:1-4.
36. Hoekzema R, Murray PI, Kijlstra A (1990): Cytokines and intraocular inflammation. Curr Eye Res 9(Suppl.):207-211.
37. Hylkema HA (1988): The role of the immune system in uveitis induced in animals. Doc Ophthalmol 70:339-351.
38. Issazadeh S, Ljungdahl A, Hojeberg B, Musiafa M, Olsson T (1995): Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis-Dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor a and tumor necrosis factor β. J Neuroimmunol 61:205-212.
39. Jacob CO, McDevitt HO (1988): Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature 331:356-358.
40. Kulkarni PS, Mancino M (1993): Studies on intraocular inflammation produced by intravitreal human interleukins in rabbits. Exp Eye Res 56:275-279.
41. Kulkarni PS, Bhattacherjee P, Paterson CA (1994): Dexamethasone inhibits interleukin-1 release in endotoxin-uveitis model. Exp Eye Res 58:637-638.
42. Li J, Perrella MA, Tsai J-C, Yet S-F, Hsieh C-M, Yoshizumi M, Patterson C, Endege WO, Zhou F, Lee M-E (1995): Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells. J Biol Chem 279:308-312.
43. Li Q, Lopez JS, Caspi RR, Roberge FG, Nussenblatt RB, Kador PF, Chan C-C ( 1993): Suppression of S-antigen-induced experimental autoimmune uveoretinitis in Lewis rats by oral administration with CGS-13080, a thromboxane synthetase inhibitor. Exp Eye Res 57:601 -608.
44. Lightman S, Greenwood J (1992): Effect of lymphocytic infiltration on the blood-retinal barrier in experimental autoimmune uveoretinitis. Clin Exp Immunol 88:473-477.
45. Lin W-L, Essner E, Shichi H (1991): Breakdown of the blood-retinal barrier in S-antigen-induced uveoretinitis in rats. Graefes Arch Clin Exp Ophthalmol 229:457-463.
46. Luna JD, Vinores SA, Derevjanik N, Campochiaro PA (1996): Mechanism of blood-retinal barrier breakdown by soluble mediators revealed by electron microscopic immunocytochemistry. Invest Ophthalmol Vis Sci 37:S967.
47. Martiney JA, Litwak M, Berman JW, Arezzo JC, Brosnan CF (1990): Pathophysiologic effect of interleukin-1β in the rabbit retina. Am J Pathol 137:1411-1423.
48. Martiney JA, Berman JW, Brosnan CF (1992): Chronic inflammatory effects of interleukin-1 on the blood-retinal barrier. J Neuroimmunol 41:167-176.
49. McMenamin PG, Broekhuyse RM, Forrester JV (1993a): Ultrastructural pathology of experimental autoimmune uveitis: A review. Micron 24:521-546.
50. McMenamin PG, Forrester JV, Steptoe R, Dua HS (1993b): Ultrastructural pathology of experimental autoimmune uveitis in the rat. Autoimmunity 16:83-93.
51. Mochizuki M, deSmet M (1994): Use of immunosuppressive agents in ocular diseases. Prog Retinal Eye Res 13:479-506.
52. Mullin JM, Snock KV (1990): Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability. Cancer Res 50:2172-2176.
53. Murata T, Ishibashi T. Khalil A, Hata Y, Yoshikawa H, Inomata H (1995): Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res 27:48-52.
54. Nakamura S, Sugita M, Tanaka S, Ohno S (1992): Enhanced production of in vitro tumor necrosis factor-α from monocytes in Behcet's disease. Nippon Ganka Gakkai Zasshi 96:1282-1285.
55. Nakamura S, Yamakawa T, Sugita M, Kijima M, lshioka M, Tanaka S-I, Ohno S (1994): The role of tumor necrosis factor-a in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci 35:3884-3889.
56. Nussenblatt RB, Rodrigues MM, Wacker W, Cevario SJ. SalinasCarmona MC, Gery I (1981): Cyclosporin A: Inhibition of experimental autoimmune uveitis in Lewis rats. J Clin Invest 67:1228-1231.
57. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K (1997): Intravitreal sustained release of VEGF causes neovascularization in rabbits and breakdown of the bloodretinal barrier in rabbits and primates. Exp Eye Res 64:505-517.
58. Paul C, Bolton C (1995): Inhibition of blood-brain barrier disruption in experimental allergic encephalomyelitis by short-term therapy with dexamethasone or cyclosporin A. Int J Immunopharmacol 17:497-503.
59. Planck SR, Huang XN, Robertson JE, Rosenbaum JT (1994): Cytokine mRNA levels in rat ocular tissues after systemic endotoxin treatment. Invest Ophthalmol Vis Sci 35:924-930.
60. Qu-Hong, Nagy JA, Senger DR, Dvorak HF, Dvorak AM (1995): Ultrastructural localization of vascular permeability factor/ vascular endothelial growth factor (VPF/VEGF) to the albuminal plasma membrane and vesiculo-vacuolar organelles of tumor microvascular endothelium. J Histochem Cytochem 43:381-389.
61. Robertson SM. Lang LS (1994): Leflunomide: Inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions 42:167-172.
62. Romer LH, McLean NV, Van HC, Daise M, Sun J, Delisser HM (1995): IFN-γ and TNF-α induce redistribution of PECAM-I (CD31) on human endothelial cells. J Immunol 154:6582-6592.
63. Rosenbaum JT, Howes EL Jr, Rubin RM, Samples JR (1988): Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol 133:47-53.
64. Rosenberg GA, Estrada EY, Dencoff JE, Steuer-Stevenson WG (1995): Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: An expanded therapeutic window. Brain Res 703:151-155.
65. Rothova A, Suttorp-vanSchulten MSA, Treffers WF, Kijlstra A (1996): Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80:332-336.
66. Schreiber SL, Crabtree GR (1992): The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136-142.
67. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983): Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985.
68. Senger DR, Perruzzi CA, Feder J, Dvorak HF (1986): A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629-5632.
69. Senger DR, Van De Water L, Brown LF, Nagy JA, Yeo K-T, Yeo T-K, Berse B, Jackman RW, Dvorak AM, Dvorak HF (1993): Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303-324.
70. Tolentino MJ, Miller JW, Gragoudas ES, Flynn E, Connally E, Chatzistefanou K, Ferrara N, Adamis AP (1996): Retinal microangiopathy induced by intravitreal injections of VEGF. Invest Ophthalmol Vis Sci 37:S119.
71. Villarroya H, Violleau K, Younes-Chennoufi AB, Baumann N (1996): Myelin-induced experimental allergic encephalomyelitis in Lewis rats: Tumor necrosis factor a levels in serum and cerebrospinal fluid. Immunohistochemical expression in glial cells and macrophages of optic nerve and spinal cord. J Neuroimmunol 64:55-61.
72. Vinores SA, Gadegbeku C, Campochiaro PA, Green WR (1989): Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. Am J Pathol 134:231-235.
73. Vinores SA, Campochiaro PA, Lee A, McGehee R, Gadegbeku C, Green WR (1990): Localization of blood-retinal barrier breakdown in human pathologic specimens by immunohistochemical staining for albumin. Lab Invest 62:742-750.
74. 1 cause breakdown of the blood-retinal barrier by opening tight junctions between vascular endothelial cells. Invest Ophthalmol Vis Sci 33:1870-1878.
75. Vinores SA, Van Niel E, Swerdloff JL, Campochiaro PA (1993a): Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. J Histochem 25:648-663.
76. Vinores SA. Van Niel S, Swerdloff JL. Campochiaro PA (1993b): Immunohistochemical evidence for the mechanism of bloodretinal barrier breakdown in galactosemic rats and its association with aldose reductase expression and inhibition. Exp Eye Res 57:723-735.
77. Vinores SA, Amin A, Derevjanik NL, Green WR, Campochiaro PA (1994): Immunohistochemical localization of blood-retinal barrier breakdown sites associated with post-surgical macular edema. Histochem J 26:655-665.
78. Vinores SA. Küchle M. Mahlow J, Chiu C, Green WR, Campochiaro PA (1995): Blood-ocular barrier breakdown in eyes with ocular melanoma: A potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol 147:1289-1297.
79. Vinores SA, Youssri AI, Luna JD, Chen Y-S, Bhargave S, Vinores MA, Schoenfeld C-L, Peng B, Chan C-C, LaRochelle W, Green WR, Campochiaro PA (1997): Upregulation of vascular endothelial growth factor in ischemie and non-ischemic human and experimental retinal disease. Histol Histopathol 12:99-109.
80. Wakefield D, Lloyd A (1992): The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine 4:1-5.
81. 2 in the adrenocorticotropin response to intravenous administration of interleukin-1β in the rat. Neuroendocrinology 62:596-600.
82. Yoshida M, Yoshimura N, Hangai M, Tanihara H, Honda Y (1994): Interleukin-1α, interleukin-1β p. and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 35:1107-1113.
83. Yosipovitch G, Shohat BA. Bshara J, Wysenbeek A, Weinberger A (1995): Elevated serum interleukin 1 receptors and interleukin 1β in patients with Behcet's disease: Correlations with disease activity and severity. Isr J Med Sci 31:345-348.